Eyam Announces Nicholas Franco Appointment to Board of Advisors

Vancouver, BC / ACCESSWIRE / June 24, 2024 / Eyam is pleased to announce the appointment of Nicholas Franco to its Board of Advisors. Mr. Franco brings a wealth of experience and strategic vision from his extensive career in the pharmaceutical industry.

Mr. Franco has held key executive positions in several prominent organizations, including his most recent role as Executive Vice President and Chief Business Development Officer at Actelion, a Janssen Pharmaceutical Company of Johnson & Johnson. His expertise in business development and commercialization has significantly contributed to growth and innovation in the companies he has served.

With over three decades of experience, Mr. Franco has been pivotal in driving business development and strategic growth in leading pharmaceutical companies. His experience spans research, marketing, sales, and business development across various therapeutic areas and geographies.

Prior to Janssen, he was the Executive Vice President and Chief Business Officer at Actelion, which was later acquired by Janssen in 2017 for $30B. At Novartis, Mr. Franco held several leadership roles, including Global Head of Negotiations and Global Head of the Neuroscience Business Franchise.

Eyam welcomes Nicholas Franco as a member of its Advisory Board. The company believes that his skills and contacts in business development will create new opportunities for Eyam's technologies. Mr. Franco expressed excitement in joining the Eyam team to maximize the value of their innovative products and technologies for difficult-to-treat diseases.